Livforsakringsbolaget Skandia Omsesidigt Sells 300 Shares of Becton, Dickinson and Company (NYSE:BDX)

Livforsakringsbolaget Skandia Omsesidigt decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 39.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 466 shares of the medical instruments supplier’s stock after selling 300 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Becton, Dickinson and Company were worth $109,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A bought a new stake in Becton, Dickinson and Company during the 4th quarter valued at about $29,000. DiNuzzo Private Wealth Inc. purchased a new position in Becton, Dickinson and Company in the fourth quarter worth about $30,000. Scarborough Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $32,000. Finally, Accordant Advisory Group Inc purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth $35,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Raymond James lowered their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $279.50.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the completion of the transaction, the executive vice president now owns 11,308 shares in the company, valued at approximately $2,676,942.84. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX traded down $0.56 during trading on Monday, hitting $235.34. 260,201 shares of the company traded hands, compared to its average volume of 1,443,282. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. The company has a market cap of $68.01 billion, a PE ratio of 51.96, a P/E/G ratio of 2.06 and a beta of 0.42. The stock’s 50-day simple moving average is $233.60 and its two-hundred day simple moving average is $236.26. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $283.78.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.96 earnings per share. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.06 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.